Literature DB >> 15136552

Hematopoietic stem cell transplantation: a primer for the primary care physician.

Chantal S Léger1, Thomas J Nevill.   

Abstract

Hematopoietic stem cell transplantation has been used for many years to treat various malignant and nonmalignant hematologic conditions. However, the high-dose conditioning regimen can lead to major organ dysfunction, life-threatening infection and bleeding. In the allogeneic setting, graft-versus-host disease may also develop, making post-transplant management complex. Once a transplant recipient is discharged from hospital and returns to his or her local community, the primary care physician can play an important role in care. Recipients of stem cell transplants may be severely immunocompromised for many months after transplantation, especially if they are still taking immunosuppressive drugs. Furthermore, endocrine and metabolic deficiencies can develop, and transplant survivors are at risk of a second malignant disease. This review is intended as a basic overview of allogeneic and autologous stem cell transplantation with a special focus on long-term follow-up issues relevant to primary care providers.

Entities:  

Mesh:

Year:  2004        PMID: 15136552      PMCID: PMC400723          DOI: 10.1503/cmaj.1011625

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  46 in total

Review 1.  Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation.

Authors:  S N Wolff
Journal:  Bone Marrow Transplant       Date:  2002-04       Impact factor: 5.483

2.  A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies.

Authors:  Stephen Couban; David R Simpson; Michael J Barnett; Christopher Bredeson; Lothar Hubesch; Kang Howson-Jan; Tsiporah B Shore; Irwin R Walker; Peter Browett; Hans A Messner; Tony Panzarella; Jeffrey H Lipton
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

3.  Reproductive status in long-term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120 mg/kg).

Authors:  A P Grigg; R McLachlan; J Zaja; J Szer
Journal:  Bone Marrow Transplant       Date:  2000-11       Impact factor: 5.483

4.  Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation.

Authors:  J Storek; A Joseph; G Espino; M A Dawson; D C Douek; K M Sullivan; M E Flowers; P Martin; G Mathioudakis; R A Nash; R Storb; F R Appelbaum; D G Maloney
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

5.  Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients.

Authors: 
Journal:  Biol Blood Marrow Transplant       Date:  2000       Impact factor: 5.742

6.  Autologous blood and marrow transplantation in patients 60 years and older.

Authors:  C S Leger; C Bredeson; B Kearns; I Bence-Bruckler; H Atkins; L Huebsch
Journal:  Biol Blood Marrow Transplant       Date:  2000       Impact factor: 5.742

Review 7.  Valaciclovir: a review of its use in the management of herpes zoster.

Authors:  D Ormrod; K Goa
Journal:  Drugs       Date:  2000-06       Impact factor: 9.546

8.  Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.

Authors:  W I Bensinger; P J Martin; B Storer; R Clift; S J Forman; R Negrin; A Kashyap; M E Flowers; K Lilleby; T R Chauncey; R Storb; F R Appelbaum
Journal:  N Engl J Med       Date:  2001-01-18       Impact factor: 91.245

9.  Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis.

Authors:  D L Forrest; T J Nevill; S C Naiman; A Le; D A Brockington; M J Barnett; J C Lavoie; S H Nantel; K W Song; J D Shepherd; H J Sutherland; C L Toze; J H Davis; D E Hogge
Journal:  Bone Marrow Transplant       Date:  2003-11       Impact factor: 5.483

10.  Semen analysis following allogeneic bone marrow transplantation. Additional data for evidence-based counselling.

Authors:  P Anserini; S Chiodi; S Spinelli; M Costa; N Conte; F Copello; A Bacigalupo
Journal:  Bone Marrow Transplant       Date:  2002-10       Impact factor: 5.483

View more
  4 in total

1.  Intravenous busulfan: in the conditioning treatment of pediatric patients prior to hematopoietic stem cell transplantation.

Authors:  Sheridan M Hoy; Katherine A Lyseng-Williamson
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

2.  Intravenous busulfan: a guide to its use as conditioning treatment before transplantation of haematopoietic progenitor cells.

Authors:  Lesley J Scott; Sheridan M Hoy; Katherine A Lyseng-Williamson
Journal:  Clin Drug Investig       Date:  2012-09-01       Impact factor: 2.859

3.  I Keep my Problems to Myself: Negative Social Network Orientation, Social Resources, and Health-Related Quality of Life in Cancer Survivors.

Authors:  Christine Rini; Yael Symes; Rebecca A Campo; Lisa M Wu; Jane Austin
Journal:  Ann Behav Med       Date:  2016-06

4.  Efficient commitment to functional CD34+ progenitor cells from human bone marrow mesenchymal stem-cell-derived induced pluripotent stem cells.

Authors:  Yulin Xu; Lizhen Liu; Lifei Zhang; Shan Fu; Yongxian Hu; Yingjia Wang; Huarui Fu; Kangni Wu; Haowen Xiao; Senquan Liu; Xiaohong Yu; Weiyan Zheng; Bo Feng; He Huang
Journal:  PLoS One       Date:  2012-04-09       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.